Last updated: February 24, 2021
Sponsor: New York State Psychiatric Institute
Overall Status: Completed
Phase
N/A
Condition
Depression (Major/severe)
Affective Disorders
Bipolar Disorder
Treatment
N/AClinical Study ID
NCT01431573
5491/7316R
IRB 5491
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- current major depressive episode (MDD, BP-I or BP-II)
- if not BP-I or BP-II, treatment refractory to ≥ 2 adequately used antidepressantshaving different mechanisms
- If BP-I or BP-II, treatment refractory to ≥ 1 standard treatment, such as lithium orvalproate
- physically healthy
- age 18-75
- not taking current antidepressants(antidepressants deemed effective will not bediscontinued
Exclusion
Exclusion Criteria:
- medically unstable condition
- past intolerance of lithium (bipolar only)
- history of (or current) psychosis or epilepsy
- current (past six months) drug or alcohol abuse/dependence
- pregnancy
- contraindication to lithium (bipolar only)
- significant retinal pathology (e.g., retinitis pigmentosa, macular degeneration)
- currently taking effective antidepressant
- cognitive dysfunction
- Parkinson's Disease
- Thyroid Stimulating Hormone > 5 milli International Units/Liter
- left ventricular hypertrophy
- symptomatic mitral valve prolapse
- abnormal creatinine
Study Design
Total Participants: 8
Study Start date:
July 01, 2011
Estimated Completion Date:
August 31, 2016
Study Description
Connect with a study center
Depression Evaluation Service - New York State Psychiatric Institute
New York, New York 10032
United StatesSite Not Available
New York State Psychiatric Institute
New York, New York 10032
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.